Is it worth buying Globus Medical stock at a price of $59.11? If this question is on your mind, make sure to check out the fundamentals of this Medical Instruments & Supplies mid-cap company:
-
Globus Medical has logged a -25.1% 52 week change, compared to -7.0% for the S&P 500
-
GMED has an average analyst rating of hold and is -11.67% away from its mean target price of $66.92 per share
-
Its trailing earnings per share (EPS) is $1.86, which brings its trailing Price to Earnings (P/E) ratio to 31.8. The Health Care sector's average P/E ratio is 24.45
-
The company's forward earnings per share (EPS) is $2.56 and its forward P/E ratio is 23.1
-
The company has a Price to Book (P/B) ratio of 3.2 in contrast to the Health Care sector's average P/B ratio is 4.16
-
The current ratio is currently 6.2, which consists in its liquid assets divided by any liabilities due within in the next 12 months
-
GMED has reported YOY quarterly earnings growth of 246.0% and gross profit margins of 0.7%
-
The company's free cash flow for the last fiscal year was $104,421,000.00 and the average free cash flow growth rate is 0.8%
-
Globus Medical's revenues have an average growth rate of 6.8% with operating expenses growing at 5.1%. The company's current operating margins stand at 23.1%